衰老中的衰老和阿尔茨海默氏病
1Department of Cellular and Integrative Physiology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, USA.
Aging and disease
|November 26, 2025
概括
细胞衰老驱动衰老和阿尔茨海默病 (AD) 通过引起中枢神经系统 (CNS) 功能障碍. 用老化剂或老形细胞向衰老细胞显示了AD治疗的前景,目前正在进行临床试验.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 细胞衰老,一种不可逆转的细胞循环停止状态,越来越多地与衰老和与年龄相关的疾病如阿尔茨海默氏症 (AD) 有关.
- 在中枢神经系统 (CNS),衰老会影响各种细胞类型,包括神经元和质细胞,导致慢性功能障碍和神经炎症.
- 像p16INK4a-pRB和p53-p21这样的关键途径,由DNA损伤驱动,诱导衰老,导致衰老相关的分泌表型 (SASP),促进炎症和组织重塑.
研究的目的:
- 审查当前对中枢神经系统衰老中的细胞衰老及其在阿尔茨海默病中的作用的理解.
- 探索新兴的治疗策略,以衰老为目标,用于AD治疗.
- 概述未来的研究方向,准确医学方法在AD.
主要方法:
- 关于细胞衰老,中枢神经系统衰老和阿尔茨海默病的现有文献的综述.
- 分析中枢神经系统中衰老触发因素,途径和标记物的分析.
- 评估老化和老形治疗策略和临床试验数据.
主要成果:
- 中枢神经系统衰老是由AD病理 (粉样β,),氧化应激和其他侮辱引起的,影响着不同的细胞类型.
- 衰老标志物在中枢神经系统中异质,需要多重检测.
- 在临床前阿尔茨海默病模型中,老化药物和老型药物显示出潜力,早期临床试验表明可行性.
结论:
- 针对细胞衰老,为阿尔茨海默病提供了一个有前途的治疗途径.
- 挑战包括生物标志物开发,通过血脑屏障传递药物,以及确定最佳干预时间.
- 未来的研究应该专注于多原子生物标志物,先进的成像和针对AD的精准医学的特定阶段干预措施.
相关概念视频
Aging
573
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
573
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Replicative Cell Senescence
4.3K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.3K
The Effect of Aging on Tissues
3.1K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
3.1K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
212
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
212


